Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of ...

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit ...

The pharma giant said amycretin led to weight loss and diabetes reductions in both injection and pill versions.

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

Novo Nordisk A/S is rated a Strong Buy with a huge unmet demand in obesity treatment and a low 13x P/E ratio. Learn more ...

Novo Nordisk is undervalued and oversold, despite strong fundamentals and a promising pipeline. The market's reaction to ...

Novo Nordisk A/S remains a Strong Buy despite semaglutide's Alzheimer's trial miss. Click for NVO growth drivers, solid ...

The Danish drugmaker's stock slumped after the company announced that a Phase II trial had failed to show positive results.

On a more positive note, Novo Nordisk reported positive results from a Phase 2 trial of its next highly promising GLP-1 ...

Novo Nordisk's amycretin cut A1C and body weight in a phase 2 study, with no plateau seen, as the company targets a 2026 ...

Novo Nordisk, whose shares have stumbled this year, on Tuesday announced a positive trial result for a weight-loss drug in ...